Autopsy report · NCT00142974
Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy
Cause of deathSlow enrollment
“This study was terminated early in April 2005 due to low patient enrollment”
Life of this trial
- Registered 1 year 4 months after it had already started.
- Ran for about 11 months before it stopped.
- 120 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis
- Sponsor type
- Industry
- Conditions
- Diabetic Gastropathy
- Interventions
- Tegaserod
- Participants
- 120
- Sites
- 1
- Countries
- Switzerland
Trials that died the same way
- The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
“This study was prematurely terminated due to low enrollment” - Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
“This study was terminated due to low participant enrollment.” - Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
“The study was terminated due to low enrollment” - A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
“This study was terminated early due to poor enrollment.” - MIRACLE EF Clinical Study
“The study was terminated early due to low enrollment.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.